NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Epidemiologic studies suggest nonsteroidal anti-inflammatory drugs (NSAIDs) offer protection against colorectal, breast, and head and neck cancers.
• Genomic insights reveal specific cancer patient subpopulations benefit from NSAID therapy.
• The PIK3CA gene, frequently mutated in solid tumors, encodes a key enzyme in the PI3K pathway, which drives tumor growth.

Purpose of the Study:

• To investigate the role of PIK3CA mutations in mediating the chemopreventive effects of NSAIDs.
• To explore the molecular mechanisms by which NSAIDs exert their protective effects in cancer.
• To identify patient subpopulations most likely to respond to NSAID treatment based on genomic alterations.

Main Methods:

• Review of epidemiologic evidence linking NSAID use to cancer risk reduction.
• Analysis of genomic data from cancer patients, focusing on PIK3CA mutations.
• Examination of preclinical models, particularly for head and neck cancer, to study NSAID mechanisms.

Main Results:

• NSAID use is associated with a protective effect against specific cancers.
• Benefit from NSAID therapy is restricted to cancer patients with PIK3CA genomic alterations in colorectal and head and neck cancers.
• PIK3CA pathway activation stimulates tumor growth and leads to increased cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) production.

Conclusions:

• The chemopreventive impact of NSAIDs is partly mediated by the inhibition of COX-2 and reduction of PGE2 levels.
• PIK3CA genomic alterations are a key biomarker for identifying patients who benefit from NSAID therapy for certain cancers.
• Targeting the PI3K/COX-2/PGE2 pathway may represent a therapeutic strategy for cancer prevention and treatment.